Asylia Therapeutics

Asylia Therapeutics

  • Founded: 2019
  • Location: Houston, TX
  • Employee range: 1 - 10
  • Clinical stage: Clin0
  • Therapy area: cancer
  • Drug types: ONC
  • Lead product: ASY-77A
  • Product link:
  • Funding: 10-50M

job board

Short description:

Antibody Therapy

Drug notes:

Contact us to add description:

Long description:

Asylia Therapeutics is developing immune-modulating therapies for the treatment of autoimmune, cancer and infectious diseases. The fundamental mechanism of immunity is the presentation of antigens to the immune system. However, tumors use a variety of mechanisms to suppress a patient's immunity avoiding immune attack. Asylia’s lead candidate, ASY-77A, enhances antigen presentation by targeting the extracellular form of the protein HSP70, a protein central to antigen delivery to the immune system. ASY-77A is an antibody product and has produced complete remission in preclinical models of various cancer types. Now Asylia is humanizing ASY-77A to initiate human safety and proof of concept trials.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy